Glaukos Announces Participation in William Blair Growth Stock Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and
pharmaceutical company focused on the development and commercialization
of novel surgical devices and sustained pharmaceutical therapies
designed to transform the treatment of glaucoma, today announced that
its management is scheduled to participate in the William Blair Growth
Stock Conference on Wednesday, June 5, 2019, at 8:00 a.m. CDT in
Chicago, IL.
A live audio webcast for this event will be available in the Investors
section of the Glaukos website at http://investors.glaukos.com
and will be archived for 90 days.
About Glaukos
Glaukos (www.glaukos.com)
is an ophthalmic medical technology and pharmaceutical company focused
on the development and commercialization of novel surgical devices and
sustained pharmaceutical therapies designed to transform the treatment
of glaucoma, one of the world’s leading causes of blindness. The company
pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the
traditional glaucoma treatment and management paradigm. Glaukos launched
the iStent®, its first MIGS device, in the
United States in July 2012 and launched its next-generation iStent
inject® device in the United States in September
2018. Glaukos is leveraging its platform technology to build a
comprehensive and proprietary portfolio of micro-scale injectable
therapies designed to address the complete range of glaucoma disease
states and progression. The company believes the iStent inject,
measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device
ever approved by the FDA.
Contacts
Chris Lewis
Director, Investor Relations, Corporate Strategy &
Development
(949) 481-0510
clewis@glaukos.com
